

### Screening Tests for Diseases (Problem)


- Currently being performed using procedures that are difficult to access
- Testing is lengthy (needs doctors and labs)
- Not in real-time (takes days for results)
- Not available to anyone, anytime
- Not scalable (pandemics)

### Market Potential for

- Pharma Companies
- Medical Device Manufacturers
- Startups

**Market 2020 (TAM) > 60 bln USD**

### Our Solution - A Unique Biotechnological Innovation

- A universal miniaturized device (USP) 
- Enabling screening for a plethora of biomolecules using multiple sensors at once with only one device (USP)
- Creating new markets (Home Testing, Individual Care B2C) (USP)
- Enhancing apheresis / dialysis treatment (B2B) (USP)
- Enabling early stage diagnostics in nephrology (B2B) (USP)
- ... with potential for many more sensors to come



### Business Model

Addressing 3 markets



### Traction

- ✓ 1<sup>st</sup> generation prototype
- ✓ First sensors developed
- ✓ First market checks done

✓ High interest from



### Competition

- ✓ Many point solutions (1 device / 1 test / 1 biomolecule)
- ✓ None offering 1 device for testing of various biomolecules with quantitative results
- ✓ None for real-time monitoring during apheresis
- ✓ None for early stage diagnosis of, e.g., chronic kidney's disease

### Funding – We Need

- ✓ EUR 300.000 in Q1 2021 for pre-commercial development
- ✓ EUR 3-5m in Q1 2022 for commercialisation

### immunoQ

Projektbranche: Life Sciences

Kundenfokus: B2B / B2C

Gründungsdatum: Jan 2021

GründerInnen:  
Thomas Werzer  
Christian Zafiu  
Martin Hammerschmid  
Peter Werzer

Email:  
thomas.werzer@univie.ac.at

Website:



Thomas Werzer  
Founder, CEO



Christian Zafiu  
Co-Founder, CSO



Martin Hammerschmid  
Co-Founder, CMO



Peter Werzer  
Co-Founder, CFO